Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
Ann Neurol. 2010 Dec;68(6):963-8. doi: 10.1002/ana.22164.
A recent controlled clinical trial suggested a role for amantadine as a treatment for pathological gambling in patients with Parkinson disease (PD). Analyzing data from a large cross-sectional study of impulse control disorders (ICDs) in PD, amantadine use (n = 728), vs no amantadine use (n = 2,357), was positively associated with a diagnosis of any ICD (17.6% vs 12.4%, p < 0.001) and compulsive gambling specifically (7.4% vs 4.2%, p < 0.001). This amantadine association remained after controlling for covariates of amantadine use, including both dopamine agonist use and levodopa dosage. Further research, including larger clinical trials, is needed to assess the role of amantadine in the development and treatment of ICDs in PD.
最近的一项对照临床试验表明，金刚烷胺可作为治疗帕金森病（PD）患者病理性赌博的一种方法。在对 PD 冲动控制障碍（ICD）的一项大型横断面研究进行数据分析时发现，与未使用金刚烷胺的患者（n = 2,357）相比，使用金刚烷胺的患者（n = 728）更易被诊断为任何 ICD（17.6%比 12.4%，p < 0.001）和强制性赌博（7.4%比 4.2%，p < 0.001）。在控制了金刚烷胺使用的相关因素（包括多巴胺激动剂的使用和左旋多巴的剂量）后，这种金刚烷胺的关联仍然存在。需要进一步的研究，包括更大规模的临床试验，以评估金刚烷胺在 PD 中 ICD 的发展和治疗中的作用。
